Sandoz in Phase III with biosimilar Humira
This article was originally published in Scrip
Executive Summary
Sandoz says it has begun Phase III testing of its biosimilar version of adalimumab (AbbVie's Humira) – the leading treatment of several autoimmune conditions including rheumatoid arthritis, psoriasis, and Crohn's disease.